ABSTRACT
Objective To investigate the therapeutic effect and adverse effects of the teniposide-based regimen in patients with primary central nervous system lymphoma (PCNSL). Methods Between March 2011 and July 2013, 16 patients with PCNSL were diagnosed and treated. The clinical characteristics, diagnosis,therapy, results and adverse effects were analyzed. Results Totally 16 patients were enrolled and diagnosed as primary central nervous system diffuse large B-cell lymphoma. All patients received teniposide-based regimen chemotherapy and 9 patients received teniposide plus rituximab. The overall response rate was 87.5 % (14/16), including 10 cases of CR and 4 cases of PR. With a median follow-up of 13.5 months, the progression-free survival (PFS) and overall survival (OS) rates of 2 years were 29.9 % and 66.7 %, respectively. The mainly hematological adverse events were neutropenia, including grade 3 in 4 cases (25 %) and grade 4 just in one case. There was one case of treatment related death. Conclusions The response rate of teniposide-based regimen for PCNSL is promising. The 2 year PFS and OS rates are even higher than results of traditional high-dose methotrexate regimen. The teniposide-based regimen is well tolerated, and the adverse events are acceptable.
ABSTRACT
Objective To compare the efficacy and adverse reaction of teniposide (VM-26) plus carboplatin (TC regimen) and etoposide (VP-16) plus carboplatin (EC regimen) in treatment of newly diagnosed small cell lung cancer (SCLC), and the possible role of VM-26 on prevention of brain metastasis of SCLC. Methods A total of 102 previously untreated SCLC patients without brain metastasis were divided into VP-16 group received EC regimen (n=64) and VM-26 group received TC regimen(n=38). The carboplatin dosages in two groups were calculated by blood concentration-area under the curve(AUC)=5, and intravenous infusion of 1 h for the first day. In VM-26 group, VM-26 70 mg/m2+normal saline 500 mL was intravenously infused of 2 h for 1-3 days. VP-16 100 mg/m2+normal saline 500 mL was given to VP-16 group, 1 h for 1-3 days. Twenty-one day was for 1 treatment cycle. The curative effect, prognosis and adverse reaction were compared between two groups. Results The overall response rates (ORR) and disease control rates (DCR) were 78.9%(30/38) and 97.4%(37/38) in VM-26 group, respectively, and 76.6%(49/64) and 95.3%(61/64) in VP-16 group, respectively, with no significant differences between the two groups (χ2=0.078 and 0.283, P0.05). The brain metastasis rate was significantly higher in VP-16 group [43.8%(28/64)] than that of VP-26 group [21.1%(8/38),χ2=5.379,P=0.02). The adverse reactions were mainly grade 1/2 bone marrow suppression in two groups. Conclusion TC is a highly active regimen for treatment of SCLC. There is no difference in the ef?fectiveness and adverse reactions versus EC. Application of VM-26 can reduce the incidence of brain metastasis in SCLC patients.
ABSTRACT
Objective:To investigate the effects of oxaliplatin (OXA) and teniposide (VM-26) on proliferation and apoptosis of gastric cancer cell line BGC-823.Methods:MTT assay was used to examine the inhibition rate of cell growth when cells were treated at various concentrations of OXA and VM-26 alone or in combination. The apoptosis was examined by flow cytometry (FCM). The protein expression of cell apoptosis associated proteins caspase-9 and livin were examined by immunocytochemistry. Results:OXA or VM-26 effectively inhibited the growth of BGC-823 gastric cancer cells in a concentration-dependent manner at certain range of concentrations. The inhibitory rate of combined treatment with OXA and VM-26 was significantly higher than that of OXA or VM-26 alone (P<0.05). The value of combination index (CI) was 0.46. The rate of apoptosis cells induced by 1.25 μg/mL OXA was 6.13%, 13.86% and 21.48% at 12, 24 and 48 h. The apoptosis rate induced by 0.625 μg/mL VM-26 was 4.60%, 10.72% and 17.07% for 12, 24 and 48 h. In combined treatment group the apoptosis rate was 11.73%, 24.14% and 44.75% at 12, 24 and 48 h, respectively. The difference was significant between combined treatment group and single drug treatment group (P<0.05). Immunnocytochemical analysis showed that the expression of caspase-9 protein was up-regulated after being exposed to OXA (1.250 μg/mL) or OXA plus VM-26 (0.750 μg/mL), while the expression rate of livin protein was down-regulated. There were significant differences among different treatment groups as well as between treatment groups and control group (P<0.05).Conclusion:OXA combined with VM-26 has synergistic effects in inhibiting the growth and inducing apoptosis of gastric cancer BGC-823 cells.
ABSTRACT
Purpose:To study the methods of treatment of spinalcord implanation medulloblatoma with combined chemotherapy. Methods:Teniposide (VM 26) 100 mg/day (dissolving in 250 ml physiological saline(N.S.)) was injected intravenously in 3 consecutive days. And it was repeated after a 7 day interval, and bleomycin A 5(PYM) 4 mg (in 250 ml N.S.) was intravenously injected twice a week. Methotrexate (MTX) 10 mg (in 5 ml N.S.) and dexamethsone 3 mg were injected intrathically once a week. The whole treatment included 5 courses and lasted about one and half month.Results:The study involved 6 cases. MRI, whick were performed 2 weeks after the treatment, showed tumors disappeared in 2 cases and 80% shrunk in 4 cases. The tumors completely disappeared after repeated treatments in the 4 cases. Conclusions:Combined chemotherapy is an efficient alternative treatment for spinalcord implanation medulloblatoma.
ABSTRACT
30% was considered sensitive and the rate ≤30% was considered resistant;and the 6 specimens were divided into 2 group according to the above standard.cDNA microassay combined with clustering analysis was used to screen for resistance-related genes.Semi-quantitative RT-PCR was used for verification of HDAC1 gene expression.Results:Three of the 6 glioma specimens belonged to the drug resistance group and the other 3 to the drug sensitive group.cDNA microarray analysis combined with cluster analysis screened out 21 genes,with 6 up-regulated and 15 down-regulated.High expression of gene HDAC1 was noticed in all the 6 specimens by semi-quantitative RT-PCR,and the trend was similar to that by microassay.Conclusion:The primary drug resistance of glioma may be associated with the 21 genes screened by cDNA microarray;the detailed mechanisms for drug controlling still need to discussed in the future.